SABCS Spin-Off | 06 - Hudis

Outside a protocol setting, dose-dense AC ->paclitaxel, administered every two weeks with growth factors, with trastuzumab during and following the paclitaxel, provides the best potential risk/benefit profile for women with HER2-positive, node-positive disease.